Streetbeat News

Analyst Ratings

BPMC

Wells Fargo analyst Derek Archila maintains an Equal-Weight rating on Blueprint Medicines (NASDAQ:BPMC) and raises the price target from $47 to $48.

Portfolio Pulse from Benzinga Newsdesk

May 23, 2023 | 11:35 am

IMVT

Credit Suisse analyst Tiago Fauth reiterated an Underperform rating on Immunovant (NASDAQ:IMVT) and maintained a $4 price target.

Portfolio Pulse from richadhand@benzinga.com

May 23, 2023 | 11:34 am

ZM

Credit Suisse analyst Fred Lee reiterated a Neutral rating on Zoom Video Communications (NASDAQ:ZM) and maintained an $83 price target.

Portfolio Pulse from richadhand@benzinga.com

May 23, 2023 | 11:32 am

BIG

Credit Suisse analyst Karen Short maintains an Underperform rating on Big Lots (NYSE:BIG) and lowers the price target from $13 to $7.

Portfolio Pulse from richadhand@benzinga.com

May 23, 2023 | 11:31 am

SHBI

Keefe, Bruyette & Woods analyst Catherine Mealor maintains a Market Perform rating on Shore Bancshares (NASDAQ:SHBI) and lowers the price target from $16 to $14.

Portfolio Pulse from Benzinga Newsdesk

May 23, 2023 | 11:31 am

MBI

Keefe, Bruyette & Woods analyst Thomas McJoynt-Griffith maintains an Outperform rating on MBIA (NYSE:MBI) but lowers the price target from $12 to $10.

Portfolio Pulse from Benzinga Newsdesk

May 23, 2023 | 11:30 am

VECT

SVB Leerink analyst Thomas Smith downgraded VectivBio Holding (NASDAQ:VECT) from Outperform to Market Perform and lowered the price target from $30 to $17.

Portfolio Pulse from richadhand@benzinga.com

May 23, 2023 | 11:29 am

FL

Goldman Sachs analyst Kate McShane maintains a Neutral rating on Foot Locker (NYSE:FL) and lowers the price target from $37 to $29.

Portfolio Pulse from Benzinga Newsdesk

May 23, 2023 | 11:29 am

CERE

Goldman Sachs analyst Madhu Kumar maintains a Neutral rating on Cerevel Therapeutics Hldg (NASDAQ:CERE) and lowers the price target from $31 to $30.

Portfolio Pulse from Benzinga Newsdesk

May 23, 2023 | 11:28 am

LLY

TD Cowen analyst Steve Scala maintains an Outperform rating on Eli Lilly (NYSE:LLY) and raises the price target from $430 to $500.

Portfolio Pulse from Benzinga Newsdesk

May 23, 2023 | 11:26 am